http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 최석경 (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
일부 제조업 남성 근로자들의 음주패턴과 수면의 질과의 관련성
최석경(Seok-Kyoung Choi),박승경(Sung-Kyong Park),조영채(Young-Chae Cho) 한국산학기술학회 2018 한국산학기술학회논문지 Vol.19 No.11
본 연구는 일부 제조업 남성 근로자들의 음주패턴과 수면의 질과의 관련성을 평가할 목적으로 시도하였다. 조사는 2017년 5월에 D 광역시의 제조업 사업장에 근무하고 있는 남성 근로자 553명을 대상으로 구조화된 무기명 자기기입식 설문지에 의한 단면조사를 실시하였다. 자료의 분석은 독립변수로 음주패턴(음주빈도와 1일 음주량을 합산하여 산정한 알코올 섭취량 및 1주간의 알코올 섭취량)을 사용하고, 종속변수로 한국어판 피츠버그수면조사표(PSQI)에 의한 수면의 질을 사용하여 로지스틱회귀분석을 실시하였다. 연구결과, 전체 조사대상자의 56.2%는 수면의 질이 좋지 않은 것으로 평가되었다. 로지스틱회귀분석 결과, 조사대상 남성 근로자들의 수면의 질이 낮을 교차비는 비음주군에 비해 주당 1회 이상 음주군에서 0.44배(95% CI=0.232-0.845) 유의하게 감소하였다. 또한 수면의 질이 낮을 교차비는 비음주군에 비해 매일 19.9g(1잔)이하의 음주 군에서 0.31배(95% CI=0.192-0.829), 매일 20.0-60.0g(1-3잔)의 음주군에서 0.28배(95% CI=0.167-0.762) 유의하게 감소하였다. 이 같은 결과는 일부 남성 근로자에서의 수면의 질은 개개인의 음주패턴이 관련하고 있음을 시사한다. The purpose of this study was to clarify whether or not alcohol drinking patterns are associated with sleep quality. A cross-sectional study was carried out by self-administered questionnaire in May, 2017 among 553 male workers who employed in manufacturing industries in D city. Logistic regression analysis was used to evaluate whether or not alcohol drinking patterns (as measured by frequency, amount of alcohol per day, and amount of alcohol per week) were associated with poor sleep quality (as measured by Pittsburgh Sleep Quality Index). As a result, in comparison with male workers who did not drink, the adjusted odds ratio for poor sleep quality was 0.44 (95% CI=0.232-0.845) for those who drank alcohol once a week or more, 0.31 (95% CI=0.192-0.829) for those who drank less than 1 glass daily, and 0.28 (95% CI=0.167-0.762) for those who drank 1-3 glasses daily. The results of this study suggest that some alcohol drinking patterns may affect sleep quality among male workers.
-
유방암 조직에서 ATP를 이용한 항암제 반응성 검사의 유용성
이희대,최석경,정준,이승아,황승현,안성귀,정우희 한국유방암학회 2010 Journal of breast cancer Vol.13 No.2
Purpose: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. Methods: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. Results: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin was higher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p=0.114, p=0.311, respectively). Conclusion: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective randomized controlled trial should be preceded.
-
Doxorubicin이 포함된 항암치료를 받은 2, 3기 유방암에서 ATP를 이용한 항암제 반응성 검사와 조기 전신 재발과의 관계
안성귀,정준,최석경,황승현,이승아,정우희,이희대 한국유방암학회 2011 Journal of breast cancer Vol.14 No.-
Purpose: An in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was designed to require only a limited number of cells and shorten test turnaround time with a high success rate. This study investigated the correlation between in vitro doxorubicin sensitivity of tumor cells and early systemic recurrence, defined as recurrence within 2 years after surgery. Methods: From January 2004 to March 2007, the ATP-CRA for doxorubicin was tested in 128 patients among breast cancer patients treated at Gangnam Severance Hospital, Seoul, Korea. The American Joint Committee on Cancer stages for all patients were II and III. All patients received doxorubicin-based chemotherapy. Selected patients were divided into a chemosensitive group and a non-chemosensitive group, according to a 40% cell death rate as a cut-off value. We analyzed the relationship between chemosensitivity and early systemic recurrence in patients with breast cancer. Results: The meanage of the patients investigated was 44.6-years-old, the mean follow-up period was 39.9 months, and recurrence free survival was 38.6 months. Thirteen recurrences were observed during follow-up. Among 13 patients with a recurrence, eight had a recurrence within 2 years (early recurrence). All of the early recurring patients belonged to the non-sensitive group. Doxorubicin sensitivity results measured by ATP-CRA were related with early recurrence free survival in patients with breast cancer (p=0.030). The mean cell death rate derived from the ATP-CRA for the early recurrence group tended to be lower than that of the non-early recurrence group, but the difference was not statistically significant (p=0.05). Conclusion: Doxorubicin sensitivity measured by ATP-CRA was well correlated with in vivo drug responsibility to predict early recurrence against doxorubicinbased adjuvant chemotherapy in patients with breast cancer.
-
ScienceON
DBpia연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
